Clinical Trials Logo

Chronic Subdural Hematoma clinical trials

View clinical trials related to Chronic Subdural Hematoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03353259 Terminated - Clinical trials for Chronic Subdural Hematoma

Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery

Start date: November 28, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Primary objectives of the study are to investigate whether adjuvant treatment in the form of Tranexamic acid (Cyklokapron) and Tocilizumab (RoAcmera) to surgery in patients with chronic subdural hematomaina can: 1. effectively decrease the rate of lesion recurrence requiring re-operation, 2. effectively shorten the time of lesion resolution. Secondary objectives of the study are:1) assess the postoperative functional outcome and quality of life of participants, 2) assess the postoperative mortality of participants, 3) assess the treatment safety data, 4) assess the cure rate of participants.

NCT ID: NCT02111785 Terminated - Clinical trials for Chronic Subdural Hematoma

Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma

DECS
Start date: March 2014
Phase: Phase 2/Phase 3
Study type: Interventional

Chronic subdural hematoma (cSDH) is condition where blood has slowly leaked out of small blood vessels surrounding the brain. Over time, the blood may cause a variety of symptoms including headache, confusion, limb weakness, and difficulty speaking. There is currently no agreement among physicians as to the best way to treat this condition. The study hypothesis to be tested was: For patients with unilateral, symptomatic chronic subdural hematoma, there is no difference in clinical outcomes, as measured by achievement of modified Rankin Score of 0-2 at 6 months, between those treated with a 2 week course of oral dexamethasone, compared with those treated with burr hole surgical drainage.